Terns Pharmaceuticals, Inc. Marketable Securities (Current)
Terns Pharmaceuticals, Inc. had Marketable Securities (Current) of $494.24 million as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-03-30
- 2025-12-31: Marketable Securities, Current $494.24M.
- 2025-09-30: Marketable Securities, Current $144.94M.
- 2025-06-30: Marketable Securities, Current $169.48M.
- 2025-03-31: Marketable Securities, Current $195.24M.
| Period end | Marketable Securities, Current |
|---|---|
| 2025-12-31 | $494.24M 10-K · filed 2026-03-30 |
| 2025-09-30 | $144.94M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $169.48M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $195.24M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $196.72M 10-K · filed 2026-03-30 |
| 2024-09-30 | $102.64M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $133.80M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $175.56M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $183.51M 10-K · filed 2025-03-20 |
| 2023-09-30 | $228.71M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $204.68M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $113.17M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $139.88M 10-K · filed 2024-03-14 |
| 2022-09-30 | $124.31M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $123.00M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $107.39M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $118.28M 10-K · filed 2023-03-27 |
| 2021-09-30 | $112.44M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $117.50M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $96.75M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-07 |